Where it lives
The intended delivery path is inside existing EHR infrastructure, including systems such as Epic, through standards like SMART on FHIR and CDS Hooks. Alerts and one-page reports appear at the point of care.
Go-to-market
Built for health systems, not another patient portal.
Astravia Analytics intends to license its clinical intelligence platform to health systems and women’s health and primary care networks. Physicians should not need a separate application or manual chart archaeology to see longitudinal historical risk. HerArc is the first module delivered on that platform.
Who it serves
Primary care physicians first, with downstream value for cardiology, endocrinology, nephrology, and women’s health programs that need a shared longitudinal view of historical risk.
Commercial model
An annual enterprise platform fee, usage-based pricing, and additional clinical modules as the same infrastructure expands beyond maternal health. Pricing assumptions are not yet validated; next work is willingness-to-pay interviews with clinical and operational leaders.
Value-based alignment
Networks are financially incentivized to prevent chronic disease progression. Connecting a documented historical event to later hypertension, diabetes, or kidney disease is a prevention intervention hiding in records that already exist.
Product sequence
HerArc first. Same spine for later domains.
HerArc is the first clinical product on a longitudinal, cross-domain prevention platform. Later modules can reuse extraction, evidence grading, and EHR delivery.
01
HerArc
Maternal and reproductive history → cardiovascular, metabolic, renal, and oncological risk. View product →
02
Adjacent history
Additional historical risk domains using the same evidence-graded architecture.
03
National, then global
Company base: Greater Seattle. Intended service area: U.S. health systems, then international expansion.
Current stage
Prototype first. Pilots next.
Astravia Analytics is in product development. HerArc is being built and tested with publicly available medical-record examples rather than collecting real patient data prematurely. Early priorities are clinician evaluation, target-population testing, and research relationships.